HLA-C and neoplasm: Tumor mutations lead to aberrant protein-coding that eventually results in the expression of tumor antigens, which could be recognized, processed and presented by major histocompatibility complexes (MHC) on antigen-presenting cells (APCs), such as dendritic cells (DCs), to cytotoxic T cells in lymph nodes.